About: Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey
Creator	Luis, Jose García Ramírez, Laura Noci, Jesus Sánchez-Azofra, María Zabana, Yamile Barreiro-De Acosta, Manuel Arranz, Eduardo Cordón, Joaquín Dolores Martín-Arranz, María Ferrer, Cristina García, Rueda
source	Medline; PMC
abstract	BACKGROUND: The outbreak of COVID-19 has rapidly evolved into a pandemic that has represented a challenge to health systems worldwide. Inflammatory bowel disease (IBD) units have been forced to change their practices to address the disease and to ensure the quality of care. METHODS: We conducted a national survey among IBD gastroenterologist members of the Spanish Working Group on Crohn’s Disease and Colitis regarding changes of practice, IBD treatments, and diagnosis and treatment of COVID-19. RESULTS: We received 54 answers from Spanish hospitals. One hundred percent of the IBD units rescheduled onsite visits to telematic consultation, and elective endoscopic and surgical procedures were delayed. Protective measures were also taken in the infusion units (100% of health centers) and hospital pharmacies, with 40.7% sending subcutaneous medications to patients. No switching between intravenous and subcutaneous anti-tumor necrosis factor drugs were made. We also found that 96.1% of IBD units advised their patients to maintain treatment if they were asymptomatic for COVID-19. For patients with COVID-19 symptoms, 92.6% of IBD units referred them to primary care or the emergency department. In addition, 7.5% of IBD units made a COVID-19 diagnosis through polymerase chain reaction and/or chest x-ray. Modifications in IBD treatment and treatment recommended for COVID-19 are also discussed. CONCLUSIONS: We report a representative national survey of changes made in the structure, diagnosis of COVID-19, and modifications in IBD treatments within IBD units.
has issue date	2020-06-04(xsd:dateTime)
bibo:doi	10.1093/ibd/izaa142
bibo:pmid	32495826
has license	no-cc
sha1sum (hex)	436e831434ab7960b7a3a1c664d8b4cca45d1fd3
schema:url	https://doi.org/10.1093/ibd/izaa142
resource representing a document's title	Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey
has PubMed Central identifier	PMC7314006
has PubMed identifier	32495826
schema:publication	Inflamm Bowel Dis
resource representing a document's body	covid:436e831434ab7960b7a3a1c664d8b4cca45d1fd3#body_text
is schema:about of	named entity 'Pandemic' named entity 'Management' named entity 'Inflammatory Bowel Disease' named entity 'EVOLVED' named entity 'National' named entity 'outbreak of COVID-19' named entity 'confidence intervals' named entity 'Spain' named entity 'biologics' named entity 'IBD' named entity 'asymptomatic carriers' named entity 'emergency department' named entity 'immunosuppressants' named entity 'statistical significance' named entity 'preventive measure' named entity 'intravenous' named entity 'infectious diseases' named entity 'IBD' named entity 'Mac OS' named entity 'IBD' named entity 'IBD' named entity 'IBD' named entity 'Stata' named entity 'immunosuppressive' named entity 'IBD' named entity 'IBD' named entity 'biologic therapies' named entity 'epidemic' named entity 'COVID-19' named entity 'immunocompromised' named entity 'surgical mask' named entity 'IBD' named entity 'immunosuppressed' named entity 'IBD' named entity 'interquartile range' named entity 'social media' named entity 'teleworking' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'endoscopic' named entity 'IBD' named entity 'COVID-19' named entity 'primary care' named entity 'general population' named entity 'sick leave' named entity 'IBD' named entity 'IBD' named entity 'nausea' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'coronavirus' named entity 'COVID' named entity 'face mask' named entity 'primary care physician' named entity 'gastroenterologists' named entity 'COVID' named entity 'intravenous' named entity 'IBD' named entity 'teleworking' named entity 'IBD' named entity 'prognosis' named entity 'biologic therapies' named entity 'IBD' named entity 'COVID' named entity 'hospital pharmacy' named entity 'subcutaneous' named entity 'Spain' named entity 'COVID-19' named entity 'epidemiological' named entity 'COVID' named entity 'primary care physician'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software